Amoéba S.A. (EPA:ALMIB)

France flag France · Delayed Price · Currency is EUR
0.9500
-0.0200 (-2.06%)
Sep 26, 2025, 5:35 PM CET
-2.06%
Market Cap65.44M
Revenue (ttm)601.60K
Net Income (ttm)-6.59M
Shares Out68.89M
EPS (ttm)-0.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume98,832
Average Volume151,665
Open0.9700
Previous Close0.9700
Day's Range0.9250 - 0.9700
52-Week Range0.4800 - 1.4400
Beta0.71
RSI52.10
Earnings DateSep 24, 2025

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is based in Chassieu, France. [Read more]

Sector Materials
Founded 2010
Employees 20
Stock Exchange Euronext Paris
Ticker Symbol ALMIB
Full Company Profile

Financial Performance

In 2024, Amoéba's revenue was 601,600, a decrease of -9.44% compared to the previous year's 664,310. Losses were -6.59 million, -53.90% less than in 2023.

Financial Statements

News

There is no news available yet.